5GZ Stock Overview
A biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Waverley Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.009 |
| 52 Week High | CA$0.015 |
| 52 Week Low | CA$0.0065 |
| Beta | 1.37 |
| 11 Month Change | 38.46% |
| 3 Month Change | 38.46% |
| 1 Year Change | -41.94% |
| 33 Year Change | -79.07% |
| 5 Year Change | n/a |
| Change since IPO | -90.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 38.5% | 0.8% | 0.8% |
| 1Y | -41.9% | -18.3% | 8.6% |
Return vs Industry: 5GZ underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 5GZ underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 5GZ volatility | |
|---|---|
| 5GZ Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5GZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5GZ's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Larry Thiessen | www.waverleypharma.com |
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. It also focuses on generic oncology injectable products. The company offers generic oncology products, such as temozolomide, capecitabine, and erlotinib.
Waverley Pharma Inc. Fundamentals Summary
| 5GZ fundamental statistics | |
|---|---|
| Market cap | €732.84k |
| Earnings (TTM) | -€1.53m |
| Revenue (TTM) | €98.26k |
7.5x
P/S Ratio-0.5x
P/E RatioIs 5GZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GZ income statement (TTM) | |
|---|---|
| Revenue | CA$144.81k |
| Cost of Revenue | CA$168.99k |
| Gross Profit | -CA$24.17k |
| Other Expenses | CA$2.23m |
| Earnings | -CA$2.25m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | -16.69% |
| Net Profit Margin | -1,555.47% |
| Debt/Equity Ratio | -112.8% |
How did 5GZ perform over the long term?
See historical performance and comparison